AbstractBackground and AimsThe IMbrave150 trial established atezolizumab–bevacizumab as the new standard of care for hepatocellular carcinoma (HCC). However, evidence on its applications in real‐world patients is limited. We report the efficacy and safety of atezolizumab–bevacizumab in a Chinese cohort of HCC patients ineligible for clinical trials.MethodsElectronic medical records of patients diagnosed with HCC and with pharmacy orders of atezolizumab and bevacizumab between 2019 and 2021 were retrospectively reviewed. Patients' demographics, performance status, stage, treatment received, adverse events and death time (if any) were recorded.ResultsThirteen eligible patients were included. mOS of HCC patients was 18.6 months [6.8–30.4], while mPFS was 9.3 months [0–19.4]. No grade 5 adverse events were reported.ConclusionsThis real‐world study provides real‐world experiences of atezolizumab–bevacizumab as first‐line and subsequent therapy in patients with unresectable HCC. Further validation on the efficacy and safety of atezolizumab–bevacizumab as second‐line or later lines of treatment should be conducted.